Postoperative Pain - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights:

• The Postoperative Pain Treatment Market is poised for growth, driven by rising demand for pain relief medications and medical devices. Globally, the increasing number of surgeries among cancer patients is a significant factor propelling market expansion. Additionally, the need for effective postoperative pain management is amplified by the slower recovery rates typically observed in elderly individuals and those undergoing medical procedures.
• Moreover, the surge in postoperative pain instances can be linked to a range of factors, with the influence of the COVID-19 pandemic being significant among them. The interruption in healthcare services and the postponement of surgeries during the pandemic resulted in a backlog of procedures.
• Despite advancements in acute pain physiology, the development of new opioid and non-opioid analgesics, innovative drug delivery methods, and the widespread adoption of minimally invasive surgical techniques aimed at reducing pain, postoperative pain remains a persistent challenge for healthcare practitioners.
• OLINVYK (oliceridine), a new G protein-biased (selective) mu-opioid receptor (MOR) ligand, has received approval in the US for managing acute pain in adults. It is eligible for reimbursement in both inpatient and outpatient settings until permanent codes are established.
• The majority of approved medications are designed for adult use, presenting a significant opportunity for pharmaceutical companies to create drugs with enhanced efficacy and reduced side effects specifically tailored for the younger demographic. Furthermore, the increasing awareness of multimodal analgesia among both clinicians and patients represents a significant advantage in addressing postoperative pain.

DelveInsight's "Postoperative Pain Drugs Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of postoperative pain, historical and forecasted epidemiology, as well as the postoperative pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Postoperative Pain Drugs Market report provides current treatment practices, emerging drugs, Postoperative Pain market share of individual therapies, and current and forecasted 7MM postoperative pain market size from 2020 to 2034. The Postoperative Pain drugs market report also covers postoperative pain treatment market practices/algorithms and Postoperative Pain unmet needs to curate the best opportunities and assess the market's potential.

Postoperative Pain Treatment Market: Overview

Postoperative pain is the expected, transient rise in baseline pain that occurs after surgery. It is a kind of pain that usually subsides in a matter of days to months, or it may be pain that is directly associated with soft tissue injury, like an ankle sprain or paper cut. Although the pain is brief, it eventually goes away as the damaged tissues heal. Each patient's experience of pain is unique and multifaceted. Preoperative psychological and pharmaceutical preparation, type of anesthesia, pain management before and after the surgical procedure, the incidence of surgical complications, and quality of postoperative care are the main factors influencing the intensity, quality, and duration of postoperative pain. Other factors include the location, type, and duration of the surgical procedure, the type and extent of the incision and surgical trauma, and the patient's physical and mental state, including their approach to pain.

Postoperative Pain Diagnosis

Appropriate and focused treatment of acute pain depends on a precise diagnosis of the kind and severity of the pain. The location and radiation of the pain, its intensity (dull, sharp, throbbing, shooting, burning, etc.), its duration (constant, intermittent, paroxysmal), its causative factors (movement, sitting position, cough, etc.), its accompanying symptoms, its quality of sleep, its assessment of the patient's expectations, its approach to pain, stress, and pain coping strategies, and its preferences for analgesic therapy are all considered in a specific evaluation of pain.

Postoperative pain Treatment

The treatment strategy for postoperative pain typically employs a multimodal approach aimed at optimizing pain relief while minimizing adverse effects and complications. Despite most surgical patients experiencing acute postoperative pain, studies indicate that less than half report satisfactory pain relief afterward. This treatment pattern encompasses both pharmacological and non-pharmacological interventions. Pharmacological therapies include various types of analgesics such as opioids, NSAIDs, acetaminophen, corticosteroids, and anesthetics. Additionally, benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids are utilized for acute pain management. Non-pharmacological approaches encompass acupuncture, psychological methods like cognitive behavioral therapy and mindfulness-based stress reduction, chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies. This comprehensive approach is known as multimodal analgesia.

Opioids are a large group of pain-relieving drugs that are used for reducing pain in postoperative cases. These drugs majorly include fentanyl, hydromorphone, morphine, oxycodone, oxymorphone, and tramadol. Examples of opioids prescribed in pill form after surgery include oxycodone. The approved opioids include Zalviso, Olinvyk (Olinvo), Dzuveo (Dsuvia), Nucynta, DepoDur, etc.

The real-world prescription analysis reveals that patients with postoperative pain commonly receive treatment with opioids, NSAIDs, corticosteroids, and anesthetics. However, there has been a concerning trend over the past decade, particularly in the US, where there has been an increasing reliance on opioids for pain management, contributing to an opioid misuse epidemic. One significant contributor to opioid misuse is their frequent prescription for severe pain after surgery or acute injuries. In contrast, evidence indicates that opioids are used less frequently in Japan compared to the US. In the US, the primary modifiable risk factors for persistent postoperative opioid use include the use of modified-release opioids, prolonged initial prescription durations, and repeated prescriptions. Opioid use and misuse are also significant issues in the UK, with recent research linking prolonged opioid use to surgical procedures.

Leading medical organizations such as the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists Committee on Regional Anesthesia strongly advocate for clinicians to consider incorporating paracetamol (acetaminophen) or NSAIDs into multimodal analgesic regimens for both adult and pediatric patients, unless there are specific contraindications. This recommendation is supported by robust evidence.

Postoperative Pain Epidemiology

As the Postoperative Pain drugs market is derived using a patient-based model, the postoperative pain epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total number of surgical procedures, total number of incident cases of postoperative pain, severity-specific incident cases of postoperative pain the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The total number of surgical procedures in the US was around 50 million in 2023.
• In 2023, there were approximately 67 million total incident cases of postoperative pain in the 7MM. These cases are expected to increase by 2034 driven by the increase in the number of traffic accidents, relative trauma injuries, and area unit needs for pain management following surgeries.
• The US contributed to the largest number of incident cases of postoperative pain ~60.41% in the 7MM in 2023. Whereas, EU4 and the UK and Japan accounted for around 21.14% and 18.43% of the total incident cases in the 7MM, respectively, in 2023.
• According to DelveInsight, in 2023, it is estimated that the severity-specific incident cases of postoperative pain in France were nearly 1.2 million, 1.5 million, and 0.8 million in mild, moderate, and severe cases and is expected to increase by 2034 with increased incidence cases of postoperative pain.
• In 2023, it is estimated that the severity-specific incident cases of postoperative pain in Germany were approximately 1.4 million, 1.7 million, and 1 million in mild, moderate, and severe cases and is expected to increase during the forecast period (2024-2034).
• The total number of surgical procedures in Japan was found to be nearly 15 million cases, out of which nearly 3 million, 5.5 million, and 3 million were of mild, moderate, and severe severity-specific incident cases of postoperative pain in 2023. These cases are expected to increase during the forecast period with the increased occurrence of the aging population in Japan which will contribute to a higher incidence of chronic conditions and comorbidities among surgical patients.

Postoperative Pain Drugs Market Chapters

The drug chapter segment of the postoperative pain therapeutics market report encloses a detailed analysis of postoperative pain-marketed drugs and mid to late-stage (Phase III and Phase II) Postoperative Pain pipeline drugs analysis. It also helps to understand the postoperative pain clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest Postoperative Pain news and press releases.

Postoperative Pain Marketed Drugs

• DEXTENZA (dexamethasone): Ocular Therapeutix

DEXTENZA is dexamethasone delivered via hydrogel technology. It is a corticosteroid indicated for treating ocular inflammation and pain following ophthalmic surgery and for treating ocular itching associated with allergic conjunctivitis.

The Ocular Therapeutix product, DEXTENZA, is only approved in the US, where it received approval in December 2018 for treating ocular pain following ophthalmic surgery. However, later in June 2019, the US FDA approved the supplemental new drug application for DEXTENZA to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication.

Ocular Therapeutics DEXTENZA contains practically all the key attributes one would want to see in a new medical product in the post-ophthalmology surgery sector, particularly cataract surgery. It allows patients to receive a whole course of steroid treatment with just one preservative-free insert, which is given by the ocular surgeon during surgery or an ophthalmologist following surgery. The current standard of treatment might call for as many as 70 steroidal eye drops to be administered over a month, with varying dose frequencies. For physicians, DEXTENZA puts control of post-surgical steroid treatment back in their hands by mitigating the risk of patient noncompliance. DEXYCU is the direct competitor of DEXTENZA because most patients will get either DEXTENZA or DEXYCU, and 100% of them are manageable for elevated IOP, even the high responders.

Postoperative Pain Emerging Drugs

• IV Tramadol: Avenue Therapeutics

IV Tramadol, is a centrally-acting synthetic analgesic of the aminocyclohexanol group with opioid-like effects. Tramadol is extensively metabolized following administration, which results in several enantiomeric metabolites that display different opioid-receptor binding properties and monoaminergic reuptake inhibition. Tramadol is a synthetic dual-acting opioid with a well-established efficacy and safety profile and has been used throughout the world for more than 30 years, accumulating an abundance of available clinical data. Oral tramadol is currently approved and marketed in the US.

Currently, the drug candidate is being investigated for post-operative surgical pain, further, they are planning to initiate a final Phase III safety study with anticipated rights in the US.

• OCS-01: Oculis

Oculis is developing OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5% mg/mL), a novel formulation of dexamethasone using Oculis proprietary Solubilizing Nanoparticle (SNP) technology. OCS-01 has completed a Phase II trial in inflammation and pain following cataract surgery (SKYGGN trial), with 153 patients providing the first POC of a once-daily topical steroid. A long-acting topical. OCS-01 has also completed another Phase II trial in DME. Following the completion of both Phase II trials, an end-of-phase II meeting was conducted with the FDA, and as per the company, the product candidate is now moving into Phase III in both indications.

Currently, the drug candidate is being investigated in a Phase III clinical trial for post-operative pain and inflammation eye, expected to be completed by July 2024.

• Opiranserin (VVZ-149) Injections: Vivozon

Opiranserin (VVZ-149) for injection, developed by Vivozon, represents a groundbreaking non-narcotic analgesic being developed to address postoperative pain. It is a non-opioid and non-NSAID analgesic candidate and is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A). Positioned as a primary treatment option in the global market, VVZ-149 aims to supplant opioid analgesics by offering an efficient and safe alternative for pain management. To tackle opioid misuse and abuse, VVZ-149 is being assessed in Phase III clinical trials in both Korea and the US.

Postoperative Pain Drugs Market Insights

The current postoperative pain treatment market consists of different approaches classified into pharmacologic and non-pharmacological therapies. The pharmacological therapies include analgesics that are further segregated into opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, etc. Acute pain is also managed by the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids. Further, non-pharmacological therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM). All these involve the concept known as multimodal analgesia.

In recent years, extensive changes have been observed in the postoperative pain management market. Opioids such as fentanyl, hydromorphone, and morphine were a gold standard, but these are being replaced by other more beneficiary approaches, such as multimodal analgesia, which has been the talk of the town. NSAIDs have become a sensible choice due to their effectiveness in pain reduction after surgical procedures. Moreover, NSAIDs have been recognized to decrease opioid consumption by less than 50%, provide superior analgesia when combined with opioids, have been proposed as first-line medications for mild-to-moderate pain, and possess several side effects. The drugs included in this category are exparel, acetaminophen, tramadol, gabanoids, gabapentin, pregabalin, and Ibuprofen.

Postoperative Pain Market Outlook

Efficient pain management is critical for patients undergoing surgery, with its physiological benefits increasingly recognized as a key postoperative quality measure. Postoperative pain management seeks to alleviate discomfort with minimal side effects, yet evidence indicates that less than half of surgical patients achieve satisfactory pain relief.

Despite the growing awareness of the value of multimodal pain management plans, opioid monotherapy remains the foundation of post-surgical pain therapy. Opioids delivered by patient-controlled analgesia support systemic analgesia for treating moderate-to-severe postoperative pain. Analgesics that act by different mechanisms and at various receptor sites are normally combined to produce additive or synergistic pain relief and can reduce opioid use. Regimens that use nonopioid analgesics include paracetamol, NSAIDs (cyclooxygenase inhibitors), alpha 2 agonists (clonidine, dexmedetomidine), gabapentin, pregabalin, ketamine, lignocaine infusions, and peripheral nerve blocks, local anesthetic wound infiltration, and continuous wound infusion techniques.

The Postoperative Pain Therapeutics Market has been categorized by drug class (Opioids, NSAIDs, Cyclooxygenase-2-selective Inhibitors (COX-2) and local anesthetics, etc.), Route of administration (injectable, oral, topical, and other routes), and distribution channels (hospital and retail pharmacies and other available channels). The expected launch of upcoming therapies and greater integration of early patient screening, medication in secondary care and other clinical settings, research on best methods for implementation, and an upsurge in awareness will eventually facilitate the development of effective treatment options.

The current Postoperative Pain Therapeutics Market segmentation is based on the off-label therapies prescribed. The drugs that are being used in the present market include bronchodilators, diuretics, antibiotics, steroids, and others. These are the major segments covered in the forecast model.

• Several key Postoperative Pain Companies are evaluating their lead candidates in different stages of clinical development like IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, and others.
• The Postoperative Pain Treatment Market is expected to experience positive growth.
• The total Postoperative Pain Treatment Market Size in the 7MM was approximately USD 2,979 million in 2023 and is projected to increase during the forecast period (2024-2034).
• The Postoperative Pain Market Size in the US was ~USD 2,606 million in 2023, which is anticipated to increase due to the increasing awareness of the disease and the launch of the emerging therapy.
• The total Postoperative Pain Market Size of EU4 and the UK was calculated to be ~USD 232 million in 2023, which was nearly 8% of the total market revenue for the 7MM.
• According to DelveInsight's estimates, among EU4 and the UK, Germany accounted for the highest market with approximately USD 72 million, followed by the UK with nearly USD 44 million in 2023.
• In 2023, Japan with a revenue of approximately USD 141 million, which was nearly 5% of the total Postoperative Pain treatment market revenue for the 7MM, which is expected to increase significantly by 2034.

Postoperative Pain Drugs Uptake

This section focuses on the uptake rate of potential Postoperative Pain drugs expected to be launched in the market during 2020-2034. For example, IV Tramadol by Avenue Therapeutics is expected to enter the US market in 2028 with a "slow" uptake.

Postoperative Pain Pipeline Development Activities

The Postoperative Pain pipeline segment provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key Postoperative Pain companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Postoperative Pain pipeline segment covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for postoperative pain.

KOL Views

To keep up with current Postoperative Pain treatment market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the postoperative pain evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the University of Utah, University of California, San Francisco, University of Michigan Medical School, US, University of Versailles-St-Quentin, University Hospital Jena, Germany, Royal College of Anesthetists, UK, Shinshu University School of Medicine, Japan were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or postoperative pain market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

According to our primary research analysis, despite advancements in the postoperative pain treatment, significant unmet needs persist in effectively managing this complex disorder. Physicians are increasingly promoting the use of multimodal analgesia in postoperative pain management to reduce dependency on opioids and lower the likelihood of opioid-related issues. However, a significant obstacle is the absence of personalized treatment approaches. Each patient's pain response is distinct and influenced by various factors like genetics, age, existing health conditions, and the type of surgery. Customizing treatment plans according to individual patient needs can enhance pain relief while reducing the potential for adverse effects and enhancing overall recovery outcomes.

According to a KOL in the US, eye drops treatment that comes in the combination of corticosteroids, NSAIDs, and antibiotics is usually preferred by clinicians after ocular surgery. Eye drops are effective only in patients who are compliant but for noncompliant patients like elderly patients, it usually becomes problematic. After the approval of Dextenza, poorly compliant patients, which are around 50%, are likely to get prescribed Dextenza.

As per another KOL, among the patients undergoing surgery in Europe, 30% experience severe postoperative pain during the first 24 h. Also, 13% of these surgical patients experience moderate to severe postoperative pain on day 3 and 9% on day 14 after the surgical procedure.

Qualitative Analysis

We perform Qualitative and Postoperative Pain treatment market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance incidence of overall adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation, and others.

Further, the therapies' safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Postoperative Pain Treatment Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The reimbursement challenges related to medical care and treatment for individuals with postoperative pain can be significant as it often requires specialized medical attention, covering the costs of diagnosis, treatment, and ongoing care. Health insurance plans may not fully cover limited coverage of some medical treatments, and therapies specific to postoperative pain. This can result in high out-of-pocket expenses for families seeking the best care for their loved ones. Moreover, it requires specialized care from healthcare providers with expertise. Finding and accessing such specialists may be challenging, and the associated costs may not always be fully reimbursed by insurance.

The Postoperative Pain report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Postoperative Pain Therapeutics Market Report Scope

• The Postoperative Pain therapeutics market report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Postoperative Pain treatment market landscape.
• A detailed review of the postoperative pain, historical and forecasted Postoperative Pain market size, Postoperative Pain market share by therapies, detailed assumptions, and rationale behind our approach are included in the report, covering the 7MM drug outreach.
• The Postoperative Pain therapeutics market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM postoperative pain therapeutics market.

Postoperative Pain Therapeutics Market Report Insights

• Patient-based Postoperative Pain Market Forecasting
• Therapeutic Approaches
• Postoperative Pain Pipeline Analysis
• Postoperative Pain Market Size
• Postoperative Pain Market Trends
• Existing and Future Postoperative Pain Therapeutics Market Opportunity

Postoperative Pain Therapeutics Market Report key strengths

• 11 years Postoperative Pain Market Forecast
• The 7MM Coverage
• Postoperative Pain Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Postoperative Pain Drugs Uptake
• Key Postoperative Pain Market Forecast Assumptions

Postoperative Pain Therapeutics Market Report Assessment

• Current Postoperative Pain Treatment Market Practices
• Postoperative Pain Unmet Needs
• Postoperative Pain Pipeline Drugs Analysis Profiles
• Postoperative Pain Therapeutics Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Postoperative Pain Therapeutics Market Insights

• What was the total Postoperative Pain Therapeutics Market, the Postoperative Pain Treatment Market Size by therapies, and Postoperative Pain Drugs Market Share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• At what CAGR, the postoperative pain therapeutics market is expected to grow at the 7MM level during the forecast period (2024-2034)?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and marketed therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Postoperative Pain Epidemiology Insights

• What are the disease risks, burdens, and Postoperative Pain unmet needs? What will be the growth opportunities across the 7MM concerning the patient population pertaining to postoperative pain?
• What is the historical and forecasted postoperative pain patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest diagnosed prevalent postoperative pain population during the forecast period (2024-2034)?
• What factors are contributing to the growth of postoperative pain cases?

Current Postoperative Pain Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the postoperative pain treatment? What are the current clinical and treatment guidelines for treating postoperative pain?
• How many companies are developing therapies for the postoperative pain treatment?
• How many emerging therapies are in the mid-stage and late stage of development for treating postoperative pain?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US?
• What is the 7MM historical and forecasted postoperative pain drugs market?

Reasons to Buy:

• The Postoperative Pain drugs market report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the postoperative pain drugs market.
• Insights on patient burden/disease Postoperative Pain Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Postoperative Pain drugs market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying upcoming solid Postoperative Pain companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies for postoperative pain, barriers to accessibility of approved therapy, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the Postoperative Pain unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.